Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
about
How to predict clinical relapse in inflammatory bowel disease patientsDietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study.Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.Progress in the treatment and outcome of pediatric inflammatory bowel disease patients.Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients.Clinical Utility of Biomarkers in IBD.Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease.The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives.Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective Study.
P2860
Q26774575-0F942374-8597-4F8B-AE38-F22249515A0EQ33786052-1E99F881-3718-4A72-9E22-8E627FF146C0Q34486456-19DDEA1E-8517-4B5B-868E-283D54D46910Q35634488-9718755D-B929-4353-9FE8-307BD205B3ACQ36056969-F87B991F-DE59-4308-8AEB-BFBBBD20ACD0Q37620361-079D8543-135B-41DD-A9BA-46ACEFBD1624Q38539968-82744993-FFC7-4356-9C54-85337849BE2EQ38609741-00C817FA-8A10-413D-BCFF-8A2948290DF6Q38683408-7662008E-6CF5-459B-8773-A17EF86A7DFBQ39251794-958BC95A-6677-4B7D-A4AE-472AB57E87EBQ39338382-DBB608C3-5B67-4D03-8B50-EDD200C8E09FQ41928544-3573C64C-D778-4B71-B258-0F2980EEBCF7Q47367020-21483F6B-2117-400C-9DC8-DFF41A4D5980Q48178445-7EC02513-3890-44D3-BAF1-2AC4AA8C370DQ52676637-EB88B3B0-B92C-4D78-A351-82D0E3E92CE9Q52878931-1323CA9D-8D6C-4027-AFD0-0B55E64473CA
P2860
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
@en
type
label
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
@en
prefLabel
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
@en
P2860
P921
P1476
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
@en
P2093
Kaija-Leena Kolho
Taina Sipponen
P2860
P356
10.3109/00365521.2014.987809
P577
2015-01-01T00:00:00Z